--- title: [Whitepaper] Ensuring Compliance for Virtual and Hybrid Pharmaceutical Companies – Challenges and Best Practices description: This whitepaper helps virtual and hybrid sponsors ensure compliance by maintaining oversight of their outsourced vendors. --- [![pace logo header white](https://info.pacelabs.com/hs-fs/hubfs/pace%20logo%20header%20white.png?width=600&height=410&name=pace%20logo%20header%20white.png) ![pace logo header](https://info.pacelabs.com/hs-fs/hubfs/pace%20logo%20header.png?width=600&height=410&name=pace%20logo%20header.png)](https://www.pacelabs.com) - [Analytical + Environmental](https://www.pacelabs.com/analytical-environmental/) - [Life Sciences](https://www.pacelabs.com/life-sciences/) - [Professional Services](https://www.pacelabs.com/professional-services/) - [Blog](https://blog.pacelabs.com/keeping-pace-with-analytical-services) ### Ensuring Compliance for Virtual and Hybrid Pharmaceutical Companies – Challenges and Best Practices  The rise of virtual and hybrid pharmaceutical companies — those that outsource all or part of their GXP operations — continues to reshape the landscape of modern drug development. While outsourcing offers strategic flexibility and financial efficiency, it does not absolve sponsor companies of regulatory accountability. Regulatory authorities hold sponsors to the same rigorous standards as fully integrated organizations, viewing contracted entities as direct extensions of the sponsor.  These innovation-driven companies depend heavily on external partners such as Contract Manufacturing Organizations (CMOs), Contract Development and Manufacturing Organizations (CDMOs), and Contract Research Organizations (CROs) to execute critical GXP activities. However, this model introduces complex quality oversight obligations that are sometimes underestimated or insufficiently prioritized without the right partner and insights. This white paper explores the key compliance challenges associated with virtual and hybrid operational models and offers best practice recommendations to help sponsors maintain robust oversight of their outsourced vendors. ### AUTHORS  **Julie Barnhill, PhD |** Senior Consultant ### **Access The Whitepaper** ##### ANALYTICAL + ENVIRONMENTAL ANALYTICAL + ENVIRONMENTAL - [Analytical + Environmental](https://www.pacelabs.com/analytical-environmental/) - [Emergency Services](https://www.pacelabs.com/analytical-environmental/emergency-disaster/) - [Statement of Qualifications](https://info.pacelabs.com/hubfs/Statement%20of%20Qualifications/Pace%20SOQ.pdf) ##### LIFE SCIENCES LIFE SCIENCES - [Life Sciences Page](https://www.pacelabs.com/life-sciences.html) - [CDMO/CRO Services](https://www.pacelabs.com/life-sciences/cdmo-cro-services/) - [Central Laboratory Services](https://www.pacelabs.com/life-sciences/central-laboratory-services/) - [Medical Device](https://www.pacelabs.com/life-sciences/medical-device/) ##### PROFESSOINAL SERVICES PROFESSOINAL SERVICES - [Professional Services](https://www.pacelabs.com/professional-services/) - [Regulatory & Compliance](https://www.pacelabs.com/professional-services/regulatory-and-compliance/) - [Scientific Staff](https://www.pacelabs.com/professional-services/scientific-staff/) - [Instrument Services](https://www.pacelabs.com/professional-services/instruments/) - [Facility Qualification](https://www.pacelabs.com/professional-services/facilities/) ##### OTHER OTHER - [Company](https://www.pacelabs.com/company/) - [Careers](https://www.pacelabs.com/careers/) - [Contact](https://www.pacelabs.com/contact-us/) - [Privacy Policy](https://www.pacelabs.com/legal-notice.html) Copyright © 2026 Pace®